Sandoz drops rituximab after US seeks more data
Sandoz will not pursue biosimilar rituximab in the US, the company has announced, following a complete response letter (CRL) from the US Food and Drug Administration (FDA) earlier this year asking for more information on the candidate. The CRL – issued in May (Generics bulletin, 11 May 2018, page 1) – came despite the firm’s biosimilar rituximab already being approved in markets such as the European Union (EU), Japan and Australia.
You may also be interested in...
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.
Amgen’s FDA submission for a biosimilar of Roche’s Rituxan rituximab brand comes shortly after Teva launched the first direct rival to the oncology drug in the US.
Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.